Delving into the Latest Updates on Recombinant Hybrid GMZ-2(Statens Serum Institute) with Synapse

Overview

Basic Info

Drug Type

Recombinant protein

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Infectious Diseases

Active Indication

Malaria, Vivax

Inactive Indication-

Originator Organization

Statens Serum Institute

Active Organization

African Malaria Network TrustUniversitaetsklinikum Tuebingen

Statens Serum Institute

+ [2]

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

ABSTRACTUsing sera from mice immunized and protected againstPlasmodium yoeliimalaria, we identified a novel blood-stage antigen gene,pypag-2. The 2.1-kbpypag-2cDNA contains a single open reading frame that encodes a 409-amino-acid protein with a predicted molecular mass of 46.8 kDa. Unlike many characterized plasmodial antigens, blocks of tandemly repeated amino acids are lacking in the pypAg-2 protein sequence. Recombinant pypAg-2, comprising the full-length protein minus the predicted N-terminal signal and C-terminal anchor sequences, was produced and used to raise a high-titer polyclonal rabbit antiserum. This antiserum was used to identify and characterize the native protein through immunoblotting, immunoprecipitation and immunofluorescence assays. Consistent with the presence of a glycosylphosphatidylinositol anchor, pypAg-2 fractionated with the detergent phase of Triton X-114-solubilized proteins and could be metabolically labeled with [3H]palmitic acid. By immunofluorescence, pypAg-2 expression was localized to both the trophozoite and merozoite membranes. Similar toPlasmodium falciparummerozoite surface protein 1, pypAg-2 contains two C-terminal epidermal growth factor (EGF)-like domains. Most importantly, immunization with recombinant pypAg-2 protected mice against lethalP. yoeliimalaria. Thus, pypAg-2 is a target of protective immune responses and represents a novel addition to the family of merozoite surface proteins that contain one or more EGF-like domains.

100 Deals associated with Recombinant Hybrid GMZ-2(Statens Serum Institute)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Malaria, Vivax	Phase 2	-	Sanaria, Inc.	-
Malaria, Vivax	Phase 2	-	Universitaetsklinikum Tuebingen	-
Malaria, Vivax	Phase 2	-	African Malaria Network Trust	-
Malaria, Vivax	Phase 2	-	European Vaccine Initiative	-
Malaria, Vivax	Phase 2	-	Statens Serum Institute	-